Engineering Medicines To Improve Patient Care

About Viridian

Viridian Therapeutics is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with TED. The company is conducting two global Phase 3 studies (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Simultaneously, the company is developing its subcutaneous program strategy with the goal of providing a potentially more conveniently administered therapy to patients with TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of FcRn inhibitors with the potential to be developed in multiple autoimmune diseases. Viridian is also developing additional preclinical assets in autoimmune and rare diseases.

Leadership

Steve Mahoney

Steve Mahoney

President and Chief Executive Officer

Read Bio >
Tom Beetham

Tom Beetham

Chief Operating Officer

Read Bio >
Shan Wu, Ph.D.

Shan Wu

Chief Business Officer

Read Bio >
Rob Henderson

Rob Henderson, Ph.D.

Chief Scientific Officer

Read Bio >
Thomas Ciulla

Thomas Ciulla, M.D., M.B.A.

Chief Development Officer

Read Bio >
Tony Casciano

Tony Casicano

Chief Commerical Officer

Read Bio >
Seth Harmon

Seth Harmon

Senior Vice President of Finance and Accounting

Read Bio >
Vahe Bedian

Vahe Bedian, Ph.D.

Co-Founder and Scientific Advisor

Read Bio >
Barrett Katz, M.D., M.B.A.

Barrett Katz, M.D., M.B.A.

Chief Medical Officer

Read Bio >

Board of Directors

Arlene Morris

Arlene Morris

Chief Executive Officer, Willow Advisors

Read Bio >
Peter Harwin

Peter Harwin

Managing Member, Fairmount Funds Management LLC

Read Bio >
Tomas Kiselak

Tomas Kiselak

Managing Member, Fairmount Funds Management LLC

Read Bio >
Jennifer Moses

Jennifer Moses

Chief Financial Officer, Investors Management Corporation

Read Bio >
Sarah Gheuens

Sarah Gheuens, M.D., Ph.D.

Chief Medical Officer, Head of R&D, Agios Pharmaceuticals

Read Bio >
Steve Mahoney

Steve Mahoney

President and Chief Executive Officer

Read Bio >